GlassScriptPhysician profile
Diego H Aviles
NPI 1538182548
$14,638.03
in general payments reported to CMS, 2019-2025
11 companies · $5,320 in 2025
The $5,320 reported for 2025 was more than what 88% of Pediatric Nephrology providers received nationally (typical 2025 total: $131).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.07 · 2020: $171 · 2021: $2,080 · 2022: $1,843 · 2023: $3,142 · 2024: $2,043 · 2025: $5,320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Food and Beverage: $306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,200.00 |
| Food and Beverage | $305.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $14,026.42 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $254.37 | 2019-2024 | Ultomiris |
| Horizon Therapeutics Plc | $123.69 | 2023 | Procysbi |
| Alnylam Pharmaceuticals INC. | $48.94 | 2021-2024 | Oxlumo |
| Azurity Pharmaceuticals, INC. | $39.43 | 2020-2023 | Eprontia, Qbrelis, Zonisade |
| Pfizer INC. | $35.37 | 2025 | |
| Eurofins Viracor, LLC | $31.83 | 2021 | |
| Apellis Pharmaceuticals, INC. | $25.45 | 2025 | Empaveli |
| Xeris Pharmaceuticals, INC. | $19.39 | 2025 | Keveyis |
| Grifols USA, LLC | $19.39 | 2022 | |
| Vantive US Healthcare LLC | $13.75 | 2025 | Renal - Acute |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diego Aviles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.